We are live on ! Find out more
SCPS

Scopus BioPharma Inc. Common Stock
SCPS

Delisted

SCPS was delisted on the 16th of December, 2022.

Back to rankings

15 hedge funds and large institutions have $111K invested in Scopus BioPharma Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% less funds holding

Funds holding: 17 → 15 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

62% less capital invested

Capital invested by funds: $293K → $111K (-$182K)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
15
Holders Change
-2
Holders Change %
-11.76%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
YIH
Y-Intercept (HK)
Hong Kong
+$3.97K
2
UBS Group
UBS Group
Switzerland
+$782
3
Morgan Stanley
Morgan Stanley
New York
+$1

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$25.3K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$24K
3
HF
HRT Financial
New York
-$15.9K
4
BCM
Bridgeway Capital Management
Texas
-$14K
5
Goldman Sachs
Goldman Sachs
New York
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$52K – – –
MRCM
2
M&R Capital Management
New Jersey
$18K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$15K -$25.3K -69,748 -53%
TRCT
4
Tower Research Capital (TRC)
New York
$6K -$590 -1,625 -6%
State Street
5
State Street
Massachusetts
$5K – – –
HF
6
HRT Financial
New York
$3K -$15.9K -43,809 -75%
First Manhattan
7
First Manhattan
New York
$3K -$4.61K -12,700 -49%
Northern Trust
8
Northern Trust
Illinois
$3K – – –
YIH
9
Y-Intercept (HK)
Hong Kong
$2.65K +$3.97K +10,940 New
CLOS
10
Compagnie Lombard Odier SCmA
Switzerland
$1K – – –
JP Morgan Chase
11
JP Morgan Chase
New York
$1K – – –
UBS Group
12
UBS Group
Switzerland
$1K +$782 +2,154 +2,154%
Vanguard Group
13
Vanguard Group
Pennsylvania
– -$24K -54,649 Closed
BCM
14
Bridgeway Capital Management
Texas
– -$14K -32,966 Closed
Goldman Sachs
15
Goldman Sachs
New York
– -$7K -17,405 Closed
Wells Fargo
16
Wells Fargo
California
– -$7 -20 -22%
Morgan Stanley
17
Morgan Stanley
New York
– +$1 +2 New

SCPS Hedge Fund Activity: Q3 2022 in Review

15 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q3 2022, worth a combined $111K — down 62% from $293K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of SCPS and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 1 added.

The largest buyer was Y-Intercept (HK), opening a new position worth an estimated $3.97K. The largest seller was Renaissance Technologies, cutting an estimated $25.3K.

  • 15 institutional investors held Scopus BioPharma Inc. Common Stock (SCPS) as of Q3 2022, down from 17 in Q2 2022.
  • Funds reported $111K of Scopus BioPharma Inc. Common Stock stock for Q3 2022, down 62% quarter-over-quarter.
  • 2 funds opened new Scopus BioPharma Inc. Common Stock positions in Q3 2022 and 4 closed out, a net change of -2 holders.
  • The largest Scopus BioPharma Inc. Common Stock buyer in Q3 2022 was Y-Intercept (HK), an estimated $3.97K added.
  • The largest Scopus BioPharma Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $25.3K sold.

Based on aggregated 13F filings for Q3 2022.